SCHEMBL10150852

SCHEMBL10150852

CCC(C)(C)C(=O)OCCCCCCCCCCCCOCC(=O)C(F)(F)S(=O)(=O)O/N=C(\c1ccccc1)C(F)(F)F

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 6/20 0.38
HDAC2 Q92769 6/20 0.38
CES2 O00748 1/20 0.36
CHRM2 P08172 2/20 0.32
CHRM4 P08173 2/20 0.32
CHRM1 P11229 2/20 0.32
CHRM3 P20309 2/20 0.32
HDAC3 O15379 2/20 0.31
HDAC4 P56524 2/20 0.31
HDAC7 Q8WUI4 2/20 0.31
HDAC10 Q969S8 2/20 0.31
HDAC11 Q96DB2 2/20 0.31
HDAC8 Q9BY41 2/20 0.31
HDAC6 Q9UBN7 2/20 0.31
HDAC9 Q9UKV0 2/20 0.31
HDAC5 Q9UQL6 2/20 0.31
TDP1 Q9NUW8 1/20 0.31
PLA2G2D Q9UNK4 1/20 0.31
FKBP1A P62942 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10150850 0.90 TDP1 (0.35) HDAC1HDAC2CHRM2CHRM4CHRM1
SCHEMBL10150854 0.90 TDP1 (0.35) HDAC1HDAC2CHRM2CHRM4CHRM1
SCHEMBL10150848 0.86 POLB (0.33) CHRM2CHRM4CHRM1CHRM3TDP1
SCHEMBL12705110 0.86 POLB (0.33) CHRM2CHRM4CHRM1CHRM3TDP1
SCHEMBL10150830 0.78 TDP1 (0.38) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL10150847 0.76 TDP1 (0.43) HDAC1HDAC2TDP1
SCHEMBL10150831 0.76 TDP1 (0.43) HDAC1HDAC2TDP1
SCHEMBL10150835 0.73 PPARA (0.32) CES2TDP1
SCHEMBL16282577 0.72 TDP1 (0.32) TDP1
SCHEMBL10186087 0.72 SRC (0.41) CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173350-B2 Oxime compound and resist composition containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-08 US disclosed
US-20100021847-A1 Oxime Compound and Resist Composition Containing the Same SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021847-A1 Oxime Compound and Resist Composition Containing the Same CYC1, UQCRB, CBR1 HDAC1 1351/4885HDAC2 1583/4885CES2 1466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.